Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Amgen Inc. (AMGN) Investigation
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Amgen Inc. (AMGN) Investigation
If you are aware of any facts relating to this investigation or purchasedAmgen shares, you can assist this investigation by visiting the firm's site: . You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. NEW YORK, NY / ACCESSWIRE / April 28, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amgen Inc. ("Amgen" or the "Company") (NASDAQ:AMGN) . Investors who purchased Amgen securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: .
纽约，NY/ACCESSWIRE/2022年4月28日/Bronstein，Gewirtz&Grossman，LLC正在代表安进的买家调查潜在的索赔。(纳斯达克：AMGN)。鼓励购买安进证券的投资者通过访问该公司的网站获取更多信息并协助调查：
The investigation concerns whether Amgen and certain of its officers and/or directors have violated federal securities laws.
调查涉及安进及其某些高管和/或董事是否违反了联邦证券法。
On April 27, 2022, Amgen disclosed in its first quarter 2022 earnings release that "[o]n April 18, 2022, Amgen received a notice of deficiency from the [Internal Revenue Service ('IRS')] for the 2013-2015 period proposing adjustments primarily related to the allocation of profits between certain of the Company's entities in the United States and the U.S. territory of Puerto Rico" which "seeks to increase Amgen's U.S. taxable income for the 2013-2015 period by an amount that would result in additional federal tax of approximately $5.1 billion, plus interest." The Company also disclosed that the IRS "notice proposes penalties of approximately $2 billion." On this news, Amgen's stock price fell sharply during intraday trading on April 28, 2022.
2022年4月27日，安进在其2022年第一季度收益报告中披露：[o]2022年4月18日，安进收到了一份缺货通知[美国国税局(IRS)]在2013-2015年期间，建议的调整主要与公司在美国的某些实体和美国领土波多黎各之间的利润分配有关“，该调整”旨在增加安进在2013-2015年期间在美国的应纳税所得额，这将导致约51亿美元的额外联邦税外加利息。该公司还披露，美国国税局的“通知”建议罚款约20亿美元。受此消息影响，安进的股票价格在2022年4月28日的盘中大幅下跌。
If you are aware of any facts relating to this investigation or purchasedAmgen shares, you can assist this investigation by visiting the firm's site: . You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
如果您知道与此次调查有关的任何事实或购买了安进股票，您可以访问公司的网站来协助调查：您也可以联系佩雷茨·布朗斯坦或他的投资者关系分析师，Bronstein，Gewirtz&Grossman，LLC的雅尔·内桑森，电话：212-697-6484。
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein，Gewirtz&Grossman，LLC是一家公司诉讼精品公司。我们的主要专长是代表我们的客户积极寻求诉讼索赔。除了在集体诉讼证券诉讼中代表机构和其他投资者原告外，该事务所的专业知识还包括一般公司和商业诉讼以及证券仲裁。律师广告。以前的结果并不能保证类似的结果。
Contact:
联系方式：
Bronstein, Gewirtz & Grossman, LLC
布朗斯坦，Gewirtz&Grossman，LLC
Peretz Bronstein or Yael Nathanson
佩雷茨·布朗斯坦或雅尔·内桑森
212-697-6484 | info@bgandg.com
212-697-6484|INFO@bgandg.com
SOURCE: Bronstein, Gewirtz and Grossman, LLC
资料来源：Bronstein，Gewirtz and Grossman，LLC
View source version on accesswire.com:
在accesswire.com上查看源代码版本：
COMTEX_406396662/2457/2022-04-28T14:25:32
Comtex_406396662/2457/2022-04-28T14：25：32
